Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemorrhagic fever with renal syndrome bivalent vaccine (Vero cell)
- Development stage
- Unknown
- Lead developer
- Zhejiang Vacin Biomedicine
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The inactivated HFRS vaccine from AIM Honesty is a bivalent inactivated viral vaccine developed for the prevention of Hemorrhagic Fever with Renal Syndrome (HFRS). Produced using Vero cells as a substrate, the vaccine contains chemically inactivated Hantaan and Seoul virus strains, which are the primary hantaviruses responsible for HFRS in China. The formulation includes an aluminum hydroxide adjuvant to enhance the immune response. The vaccine received New Drug Application (NDA) approval in China in 2007 and is marketed by subsidiaries of AIM Vaccine Co., Ltd., including AIM Honesty and AIM Persistence. It is currently part of the commercialized vaccine portfolio distributed across China.
- Brand names
- haemorrhagic fever with renal syndrome bivalent vaccine (Vero cell)
- Other names
- Inactivated HFRS VaccineHFRS vaccine (Vero cell)Bivalent inactivated HFRS vaccineinactivated HFRS vaccine-AIM Honesty-inactivated viral vaccine-Hemorrhagic Fever with Renal Syndrome (HFRS)
02
Targets
HTNV (Hantaan orthohantavirus)SEOV (Seoul orthohantavirus)
Beyond the preview
Go deeper on haemorrhagic fever with renal syndrome bivalent vaccine (Vero cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemorrhagic fever with renal syndrome bivalent vaccine (Vero cell).